Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases

Ugurluer G, Schneiders FL, Corradini S, Boldrini L, Kotecha R, Kelly P, Portelance L, Camilleri P, Ben-David MA, Poiset S, Marschner SN, Panza G, Kutuk T, Palacios MA, Castelluccia A, Zoto Mustafayev T, Atalar B, Senan S, Ozyar E (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Clinical and Translational Radiation Oncology Elsevier

Book Volume: 46

Article Number: 100756

DOI: 10.1016/j.ctro.2024.100756

Abstract

Purpose: Stereotactic body radiotherapy (SBRT) is an effective treatment for adrenal gland metastases, but it is technically challenging and there are concerns about toxicity. We performed a multi-institutional pooled retrospective analysis to study clinical outcomes and toxicities after MR-guided SBRT (MRgSBRT) using for adrenal gland metastases. Methods and Materials: Clinical and dosimetric data of patients treated with MRgSBRT on a 0.35 T MR-Linac at 11 institutions between 2016 and 2022 were analyzed. Local control (LC), local progression-free survival (LPFS), distant progression-free survival (DPFS) and overall survival (OS) were estimated using Kaplan-Meier method and log-rank test. Results: A total of 255 patients (269 adrenal metastases) were included. Metastatic pattern was solitary in 25.9 % and oligometastatic in 58.0 % of patients. Median total dose was 45 Gy (range, 16–60 Gy) in a median of 5 fractions, and the median BED10 was 100 Gy (range, 37.5–132.0 Gy). Adaptation was done in 87.4 % of delivered fractions based on the individual clinicians' judgement. The 1- and 2- year LPFS rates were 94.0 % (95 % CI: 90.7–97.3 %) and 88.3 % (95 % CI: 82.4–94.2 %), respectively and only 2 patients (0.8 %) experienced grade 3 + toxicity. No local recurrences were observed after treatment to a total dose of BED10 > 100 Gy, with single fraction or fractional dose of > 10 Gy. Conclusions: This is a large retrospective multi-institutional study to evaluate the treatment outcomes and toxicities with MRgSBRT in over 250 patients, demonstrating the need for frequent adaptation in 87.4 % of delivered fractions to achieve a 1- year LPFS rate of 94 % and less than 1 % rate of grade 3 + toxicity. Outcomes analysis in 269 adrenal lesions revealed improved outcomes with delivery of a BED10 > 100 Gy, use of single fraction SBRT and with fraction doses > 10 Gy, providing benchmarks for future clinical trials.

Involved external institutions

Thomas Jefferson University Hospitals US United States (USA) (US) Klinikum der Universität München (LMU Klinikum) DE Germany (DE) Fondazione Policlinico Universitario Agostino Gemelli IRCCS IT Italy (IT) Ospedale San Pietro Fatebenefratelli IT Italy (IT) Acibadem Maslak Hospital / Acıbadem Maslak Hospital TR Turkey (TR) Acıbadem Üniversitesi TR Turkey (TR) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra NL Netherlands (NL) Baptist Health South Florida US United States (USA) (US) Orlando Health US United States (USA) (US) University of Miami US United States (USA) (US) GenesisCare AU Australia (AU) Assuta Medical Center IL Israel (IL)

How to cite

APA:

Ugurluer, G., Schneiders, F.L., Corradini, S., Boldrini, L., Kotecha, R., Kelly, P.,... Ozyar, E. (2024). Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases. Clinical and Translational Radiation Oncology, 46. https://doi.org/10.1016/j.ctro.2024.100756

MLA:

Ugurluer, Gamze, et al. "Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases." Clinical and Translational Radiation Oncology 46 (2024).

BibTeX: Download